The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies

Medicine and Dentistry

• Immunotherapy 100%
• Hepatocellular Carcinoma 100%
• Systemic Therapy 100%
• Sorafenib 100%
• Tyrosine-Kinase Inhibitor 40%
• Overall Survival 20%
• Liver Function 20%
• Immunoglobulin 20%
• Combination Therapy 20%
• Pembrolizumab 20%
• Nivolumab 20%
• Immune Checkpoint Inhibitor 20%
• Ramucirumab 20%
• Lenvatinib 20%
• Regorafenib 20%
• Monotherapy 20%
• Cabozantinib 20%
• Elevated Alpha-Fetoprotein 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Liver Cell Carcinoma 100%
• Systemic Treatment 100%
• Sorafenib 100%
• Protein Tyrosine Kinase Inhibitor 40%
• Alpha Fetoprotein 20%
• Monotherapy 20%
• Immune Checkpoint Inhibitor 20%
• Cabozantinib 20%
• Overall Survival 20%
• Combination Therapy 20%
• Immunoglobulin 20%
• Pembrolizumab 20%
• Lenvatinib 20%
• Ramucirumab 20%
• Regorafenib 20%